This story originally appeared on Zacks
Ligand Pharmaceuticals (LGND) shares rallied 4.5% in the last trading session to close at $146.03. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock’s 13% loss over the past four weeks.
Ligand’s drug-developing technologies have significant potential to drive the company’s growth. The prospects of these technologies are driving Ligand’s share price.
This drugmaker is expected to post quarterly earnings of $1.38 per share in its upcoming report, which represents a year-over-year change of -14.8%. Revenues are expected to be $62.7 million, down 10.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ligand, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on LGND going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research